No clinical difference at mid-term follow-up between TiN-coated versus uncoated cemented mobile-bearing total knee arthroplasty: a matched cohort study

Deroche, Etienne; Batailler, Cécile; Shatrov, Jobe; Gunst, Stanislas; Servien, Elvire; Lustig, Sébastien

doi:10.1051/sicotj/2023001

Cited by 4 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The data support that the ACS III system provided excellent long-term outcomes and is well suited for the treatment of end-stage osteoarthritis of the knee joint when compared to other cemented systems. This is in line with a recent systematic review that reported that TiN-coated prostheses are not inferior to uncoated TKAs [ 18 ] and a mid-term follow-up matched-cohort study that reported satisfactory clinical outcomes and low revision rates for TiN-coated TKA [ 19 ]. Van Es et al showed no difference in mid-term survival and function among cemented, uncemented, and hybrid fixation in mobile-bearing ACS TKA [ 20 ].…”

Section: Discussionsupporting

confidence: 89%

Long-term clinical and radiological outcome of a cementless titanium-coated total knee arthroplasty system

Hörlesberger,

Smolle,

Leitner

et al. 2023

Arch Orthop Trauma Surg

View full text Add to dashboard Cite

Introduction To ensure a high-quality standard, it is important to frequently evaluate different prostheses models to avoid prostheses with high failure rates. Thus, the aim of the study was to evaluate the long-term outcome of the uncemented titanium-coated total knee arthroplasty (TKA) system (Advanced Coated System (ACS) III, Implantcast, GERMANY). We hypothesized that the ACS III would have a similar performance as other cemented TKA systems. Materials and methods A total of 540 ACS III mobile-bearing knee joint prostheses were implanted in 495 patients. The visual analogue scale (VAS) score, Tegner activity score (TAS), knee society score (KSS), Western Ontario and McMaster (WOMAC) score, and the Short Form 12 (SF-12) score for the evaluation of quality of life (QoL) were taken after at least 9 years of follow-up. In addition, we measured range of motion (ROM) and assessed potential sex differences. In addition, the survival analysis was calculated at a median follow-up of 16.7 years. Results At the final follow-up, 142 patients had died, and 38 had been lost to follow-up. The rate of revision-free implant survival at 16.7 years was 90.0% (95% CI 87.1–92.2%) and the rate of infection-free survival was 97.0% (IQR 95.2–98.2%). The reasons for revision surgery were aseptic loosening (32.9%), followed by infection (27.1%), inlay exchange (15.9%), and periprosthetic fractures (5.7%). At the clinical follow-up visit, the mean VAS score was 1.9 ± 1.9, the median TAS was 3 (IQR 2–4), and the mean KSS for pain and function were 83.5 ± 15.3 and 67.5 ± 25.2, respectively. The mean WOMAC score was 81.1 ± 14.9, and the median SF-12 scores for physical and mental health were 36.9 (IQR 29.8–45.1) and 55.8 (IQR 46.2–61.0), respectively. The mean knee flexion was 102.0° ± 15.4°. Male patients had better clinical outcome scores than female patients [SF-12 mental health score, p = 0.037; SF-12 physical health score, p = 0.032; KSS pain score (p < 0.001), and KSS functional score (p < 0.001)]. Conclusion The ACS III TKA system is a suitable option for the treatment of end-stage osteoarthritis of the knee joint because of its adequate long-term survival. Our findings are in line with published data on similar TKA systems that have shown favourable clinical scores in males. Level of evidence Level III—Retrospective cohort study.

show abstract

Section: Discussionsupporting

confidence: 89%